

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. 156

(68) PATENT NO. : 8,101,659
(45) ISSUED : January 24, 2012
(75) INVENTOR : Gary M. Ksander et al.
(73) PATENT OWNER : Novartis Pharmaceuticals Corporation
(95) PRODUCT : ENTRESTO® (sacubitril and valsartan)

This is to certify that an application under 35 U.S.C. 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 8,101,659 based upon the regulatory review of the product ENTRESTO® (sacubitril and valsartan) by the Food and Drug Administration. According to United States Patent and Trademark Office records, the original expiration date of the patent as of the date of issuance of this certificate is January 14, 2023. Because it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 732 days

subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. 156.

I have caused the seal of the United States Patent and Trademark Office to be affixed this 23rd day of August 2021.



A handwritten signature in black ink, appearing to read "Drew Hirshfeld", written over a horizontal line.

Drew Hirshfeld
Commissioner for Patents, Performing the Functions and Duties
of the Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office